#25

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Havenga et al.

Serial No.: 09/348,354

Filed: 7/7/1999

For: CHIMAERIC ADENOVIRUSES

Examiner: G. Leffers Jr.

Group Art Unit: 1636

Attorney Docket No.: 2578-4123.2US

CERTIFICATE OF TRANSMISSION

I heretry centrity that this correspondence is being facsimile transmitted to the Commissioner for Patents (Fax No. (703) 746-5114) on the date shown below.

March 6, 2002

Date

Signature of registered practitioner or other person having reasonable basis to expect transmission to occur on date shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Shown G. Hensen

Typed/printed name of person whose signature is contained above

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 or PTO/SB/08A be considered by the Examiner and made of record. A copy of the listed document is enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Attorney Docket: 2578-4123.2US

Other Documents

DE JONG et al., Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively, Journal of Clinical Microbiology, Dec. 1999, p. 3940-45, Vol. 37, No. 12, American Society for Microbiology.

Applicants offer to supply any explanation or discussion of the document which the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of the final action. The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,

Shawn G, Hansen

Registration No. 42,627

Attorney for Applicants

TRASKBRITT

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: March 6, 2002

SGH/bv

Enclosures: Form PTO-1

Form PTO-1449 or PTO/SB/08A

Copy of documents cited